These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 28778937)
1. Gene Expression Signatures in Circulating Tumor Cells Correlate with Response to Therapy in Metastatic Breast Cancer. Bredemeier M; Edimiris P; Mach P; Kubista M; Sjöback R; Rohlova E; Kolostova K; Hauch S; Aktas B; Tewes M; Kimmig R; Kasimir-Bauer S Clin Chem; 2017 Oct; 63(10):1585-1593. PubMed ID: 28778937 [TBL] [Abstract][Full Text] [Related]
2. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. Bredemeier M; Edimiris P; Tewes M; Mach P; Aktas B; Schellbach D; Wagner J; Kimmig R; Kasimir-Bauer S Oncotarget; 2016 Jul; 7(27):41677-41690. PubMed ID: 27223437 [TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy. Aaltonen KE; Novosadová V; Bendahl PO; Graffman C; Larsson AM; Rydén L Oncotarget; 2017 Jul; 8(28):45544-45565. PubMed ID: 28489591 [TBL] [Abstract][Full Text] [Related]
4. Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success. Ušiaková Z; Mikulová V; Pintérová D; Brychta M; Valchář J; Kubecová M; Tesařová P; Bobek V; Kološtová K In Vivo; 2014; 28(4):605-14. PubMed ID: 24982230 [TBL] [Abstract][Full Text] [Related]
5. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer. Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599 [TBL] [Abstract][Full Text] [Related]
6. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). Magbanua MJM; Rugo HS; Wolf DM; Hauranieh L; Roy R; Pendyala P; Sosa EV; Scott JH; Lee JS; Pitcher B; Hyslop T; Barry WT; Isakoff SJ; Dickler M; Van't Veer L; Park JW Clin Cancer Res; 2018 Mar; 24(6):1486-1499. PubMed ID: 29311117 [No Abstract] [Full Text] [Related]
7. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy. Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991 [TBL] [Abstract][Full Text] [Related]
8. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222 [TBL] [Abstract][Full Text] [Related]
9. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508 [TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients. Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361 [TBL] [Abstract][Full Text] [Related]
11. Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease. Matuschek C; Bölke E; Lammering G; Gerber PA; Peiper M; Budach W; Taskin H; Prisack HB; Schieren G; Orth K; Bojar H Eur J Med Res; 2010; 15(7):277-86. PubMed ID: 20696638 [TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Markou A; Strati A; Malamos N; Georgoulias V; Lianidou ES Clin Chem; 2011 Mar; 57(3):421-30. PubMed ID: 21245367 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M; BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970 [TBL] [Abstract][Full Text] [Related]
14. Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy. Akkiprik M; Koca S; Uğurlu MÜ; Ekren R; Peker Eyüboğlu İ; Alan Ö; Erzik C; Güllü Amuran G; Telli TA; Güllüoğlu MB; Sezerman U; Yumuk PF Clin Breast Cancer; 2020 Aug; 20(4):332-343.e3. PubMed ID: 32201164 [TBL] [Abstract][Full Text] [Related]
15. Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells. Gorges TM; Kuske A; Röck K; Mauermann O; Müller V; Peine S; Verpoort K; Novosadova V; Kubista M; Riethdorf S; Pantel K Clin Chem; 2016 Nov; 62(11):1504-1515. PubMed ID: 27630154 [TBL] [Abstract][Full Text] [Related]
16. A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer. Strati A; Zavridou M; Kallergi G; Politaki E; Kuske A; Gorges TM; Riethdorf S; Joosse SA; Koch C; Bohnen AL; Mueller V; Koutsodontis G; Kontopodis E; Poulakaki N; Psyrri A; Mavroudis D; Georgoulias V; Pantel K; Lianidou ES Clin Chem; 2021 Oct; 67(10):1395-1405. PubMed ID: 34322698 [TBL] [Abstract][Full Text] [Related]
17. KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients. Wang XM; Zhang Z; Pan LH; Cao XC; Xiao C Breast Cancer Res Treat; 2019 Apr; 174(2):375-385. PubMed ID: 30535933 [TBL] [Abstract][Full Text] [Related]
18. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204 [TBL] [Abstract][Full Text] [Related]
19. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Wang C; Mu Z; Chervoneva I; Austin L; Ye Z; Rossi G; Palazzo JP; Sun C; Abu-Khalaf M; Myers RE; Zhu Z; Ba Y; Li B; Hou L; Cristofanilli M; Yang H Breast Cancer Res Treat; 2017 Jan; 161(1):83-94. PubMed ID: 27771841 [TBL] [Abstract][Full Text] [Related]
20. Did circulating tumor cells tell us all they could? The missed circulating tumor cell message in breast cancer. Fina E; Reduzzi C; Motta R; Di Cosimo S; Bianchi G; Martinetti A; Wechsler J; Cappelletti V; Daidone MG Int J Biol Markers; 2015 Nov; 30(4):e429-33. PubMed ID: 26349664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]